Sage Therapeutics announced plans to lay off approximately 338 employees, representing most of its workforce, after Maryland-based Supernus Pharmaceuticals' acquisition of the company. This follows frequent setbacks including clinical trial failures and limited sales of products like Zulresso and Zurzuvae. The workforce reduction will take effect in August, with unclear implications for ongoing research and development programs.